In this study, Scott Pegan, along with his colleagues, explores how nairoviruses circumvent the host’s innate defenses. A notable example of this family is the Crimean-Congo hemorrhagic fever virus (CCHFV), a pathogen with a high fatality rate posing a global threat, particularly to civilians and military personnel in endemic areas across Africa, the Middle East, and Asia. Understanding the immune evasion strategies of such viruses is critical for developing effective countermeasures and improving biosurveillance capabilities.

Nairoviruses produce a specialized enzyme—an ovarian tumor domain-containing protease—that selectively cleaves ubiquitin and ISG15 molecules attached to human proteins. Ubiquitin and ISG15 modifications typically function as alarm signals to the immune system, marking infected cells for destruction. By removing these small protein tags, nairoviruses render themselves invisible to host defenses, enabling uninterrupted replication and pathogenesis.

The investigators analyzed enzymatic activity from four different nairovirus species: three recently identified orthonairoviruses isolated from patients in Asia and an additional virus known as Pacific Coast tick nairovirus (PCTNV) found in ticks but not yet confirmed in human infections. Their assays revealed that the PCTNV enzyme exhibited the highest efficiency in cleaving ubiquitin and ISG15 from human proteins, suggesting a superior ability to suppress immune detection compared to its counterparts.

Given that PCTNV is transmitted by a tick species known to bite humans and capable of carrying other diseases such as Rocky Mountain spotted fever, these findings raise concerns about potential human exposure risks, especially along the U.S. West Coast. This highlights the urgent need for vigilance, not only regarding tick bites themselves but also concerning the species of ticks involved, as they may harbor previously unrecognized pathogens.

Expanding on this work, Pegan’s team collated ubiquitin cleavage data from 13 nairovirus species to train computational models aimed at distinguishing pathogenic viruses from less harmful ones. This represents a promising avenue toward automated biosurveillance systems capable of real-time detection and risk assessment of emerging tick-borne viruses.

Overall, this study emphasizes the complex interplay between nairoviruses and human immune defenses and underscores the importance of integrated molecular and computational approaches to tackle the growing threat of these stealthy viral pathogens.

Subject of Research: Immune evasion mechanisms of nairoviruses, a class of tick-borne viruses
Article Title: How an emerging class of tick-borne viruses escape human immune defenses
News Publication Date: 13-Jul-2026
Web References: http://dx.doi.org/10.1021/acsinfecdis.6c00320

Keywords

Viruses, Nairoviruses, Tick-borne pathogens, Immune evasion, Ubiquitin, ISG15, Protease, Biosurveillance

Hantaviruses have been predominantly identified in the Americas, Europe, and Asia, with an intriguing dual clinical manifestation largely dictated by geographic viral strain variation. In the Americas, notably, the hantavirus cardiopulmonary syndrome (HCPS) represents a severe respiratory illness characterized by rapid progression and high fatality if untreated. Contrarily, the old-world hantavirus strains tend to induce hemorrhagic fever with renal syndrome (HFRS), a condition that affects vascular permeability and renal function with profound clinical consequences. The incubation period for these syndromes generally spans two to four weeks, during which infected individuals experience nonspecific symptoms such as fever, headaches, myalgia, and gastrointestinal discomfort, complicating early clinical suspicion.

The transmission of hantavirus is primarily zoonotic, attributable to contact with infected rodent excreta, especially in rural and agricultural settings across Canadian provinces like Manitoba, Saskatchewan, Alberta, and British Columbia. Notably, the Andes strain represents a unique epidemiologic entity, as unlike other types, it exhibits documented human-to-human transmission capability, elevating its outbreak potential and public health risk profile. Diagnostic measures for hantavirus infections leverage serological assays and polymerase chain reaction (PCR) testing, executed by specialized laboratories such as the National Microbiology Laboratory in Winnipeg, enabling timely confirmation of cases.

Treatment of hantavirus infections is predominantly supportive, given current limitations in specific antiviral therapies or vaccinations. Clinical care focuses on symptom mitigation and organ support, particularly for patients manifesting respiratory compromise or renal dysfunction. Infection control policies for hantavirus, especially when the Andes virus infection is suspected, mandate strict isolation with combined airborne, droplet, and contact precautions to curtail nosocomial transmission. Expert involvement from infectious disease specialists and immediate public health notification form critical components of outbreak management.

Turning to Ebola virus disease (EVD), this viral hemorrhagic fever has a storied history of sporadic outbreaks primarily localized in Central and West Africa since its identification in 1976. The Ebola virus genus encompasses several species pathogenic to humans, with Zaire, Sudan, and Bundibugyo being the most clinically significant. Current epidemiologic data from outbreaks, such as the Bundibugyo strain expounded in the Democratic Republic of Congo, reveal case fatality rates ranging from 30 to 50 percent. Zoonotic reservoirs are believed to be fruit bats, facilitating sporadic spillover events to human populations through direct contact or via intermediate hosts such as primates.

The clinical presentation of Ebola virus disease often includes an abrupt onset of fever exceeding 38°C, profound fatigue, myalgia, and gastrointestinal symptoms such as vomiting and diarrhea. Despite its classification as a hemorrhagic fever, only a minority of patients exhibit overt bleeding manifestations. The incubation period ranges broadly from two days to three weeks, which, coupled with nonspecific initial symptoms, underscores the difficulties faced in early detection and containment. Confirmatory diagnosis relies heavily on molecular techniques, particularly real-time PCR assays that identify viral RNA in blood or other bodily fluids.

Given the high transmissibility of Ebola virus through direct contact with infected bodily fluids — including vomitus, feces, blood, semen, and contaminated surfaces — stringent infection prevention and control measures are imperative. Health Canada and global health authorities advocate for comprehensive use of personal protective equipment (PPE), including fit-tested N95 respirators, face shields, gloves, and impermeable gowns, to safeguard healthcare providers and prevent nosocomial spread. The integration of rigorous screening protocols, careful patient assessment, and isolation of suspected or confirmed cases form the bedrock of outbreak interventions.

Advancements in the prevention and treatment of Ebola virus disease have progressed significantly over recent years. Vaccination efforts, particularly targeting the Zaire ebolavirus species, have demonstrated remarkable efficacy, with the deployment of recombinant vesicular stomatitis virus-based vaccines altering the landscape of outbreak control. Additionally, therapeutic antivirals, including monoclonal antibodies and antiviral drugs, have reduced mortality rates substantially. However, the Bundibugyo ebolavirus remains recalcitrant to these advances, lacking approved vaccines or targeted treatments, thereby necessitating reliance on supportive care to manage patients afflicted with this strain.

The clinical and virological parallels between hantavirus infections and Ebola virus disease underline the criticality of robust surveillance systems and prompt laboratory diagnostics. Both diseases exemplify zoonotic spillover phenomena, emphasizing the interface between humans, wildlife, and environmental modifications that drive emerging infectious threats. The absence of widely effective antiviral therapies and the challenges inherent to early clinical distinction from other febrile illnesses highlight ongoing gaps in medical preparedness and response.

Healthcare settings remain vulnerable points for transmission of both viruses, necessitating adherence to strict IPAC protocols. Continuous education of frontline healthcare workers concerning disease recognition and transmission mechanisms is vital for mitigating in-hospital outbreaks. Moreover, public health messaging regarding the risks associated with exposure to wildlife reservoirs and infected individuals can bolster community-level preventive practices.

In summary, the growing recognition of the public health dangers posed by hantavirus and Ebola virus infections compels an integrated approach combining epidemiologic vigilance, clinical acumen, and infection control excellence. Research and development endeavors directed toward vaccines, diagnostics, and therapeutics must persist to bridge current gaps. As global interconnectedness intensifies, the containment and management of such deadly pathogens rest on the robust collaboration of clinical practitioners, researchers, and public health authorities worldwide.

Subject of Research: People
Article Title: Hantavirus and Ebola virus disease
News Publication Date: 22-Jun-2026
Web References: https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260834, https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260789
References: Canadian Medical Association Journal, National Microbiology Laboratory (Winnipeg), Health Canada guidelines
Keywords: Infectious diseases, Viruses, Hantavirus, Ebola virus, Viral hemorrhagic fevers, Zoonotic diseases, Infection prevention and control, Outbreaks, Public health

The origin of pandemics often hinges on the zoonotic leap of viruses, initially infecting humans from animal reservoirs before evolving to spread efficiently among human populations. Such a transition is critical because it marks the point at which viruses acquire adaptations that enhance transmission. For SARS-CoV-2, this leap was followed by a complex adaptive process culminating in variants that dramatically shaped the pandemic’s course, with Omicron representing the pinnacle of such evolutionary success in terms of transmissibility.

In August 2021, the initial in vitro evolution experiment conducted by Schreiber’s team already provided a glimpse into this process. By inducing mutations that improved binding affinity to human respiratory receptors, they identified a mutation pair later found in Omicron shortly after its discovery, highlighting a predictive capacity of their method. This alignment of laboratory evolution and real-world viral changes marked a paradigm shift in how we might forecast viral adaptation.

The study’s methodology involved deliberately introducing mutations into the coronavirus spike protein’s receptor-binding domain through an error-prone replication mechanism. This was followed by selective binding to human receptors, conducted in millions of baker’s yeast cells engineered to express the viral proteins. These cycles of mutation and selection accelerated the natural evolutionary process, compressing years of viral adaptation into months within a test-tube environment.

Commencing with multiple viral templates—including the ancestral Wuhan strain and notable variants Alpha and Beta—the researchers simulated two distinct evolutionary pressures. The first scenario, strong selection pressure, favored only those variants exhibiting superior receptor binding, allowing advantageous mutations to swiftly dominate. In contrast, the weak selection pressure condition permitted a broader diversity of viral forms to survive, enabling advantageous mutations to increase in frequency more gradually and without dominance.

Remarkably, under strong selection pressure, the resulting evolutionary endpoint closely resembled the Omicron variant, which rapidly superseded other forms in real-world populations from late 2021 onward. This congruence suggests that Omicron’s dominance was not an accident but rather a predictable outcome when the virus is subjected to stringent evolutionary constraints. The experiments thereby offer a blueprint for understanding how certain variants outperform others under selective forces.

Intriguingly, the research extended beyond SARS-CoV-2 to investigate SARS-CoV-1, responsible for the 2003 epidemic, which failed to cause a global pandemic. Applying strong selection pressure in vitro similarly produced viral variants with enhanced human receptor binding, though fortunately, existing partial immunity due to SARS-CoV-2’s prevalence may mitigate the risk posed by such enhanced SARS-CoV-1 forms. These insights stress the utility of this approach for studying multiple viral threats.

A lingering enigma throughout the COVID-19 crisis has been the origin of Omicron, which carries a constellation of mutations distinctly divergent from other SARS-CoV-2 lineages. Traditional wisdom posited that its extensive mutational burden arose during chronic infections in immunocompromised individuals, whose prolonged viral replication provides a crucible for intensive evolutionary pressures. The in vitro findings support this, demonstrating that strong selection scenarios—akin to those present in immunocompromised hosts—are critical for fostering Omicron-like adaptations.

Under weak selection pressure, such evolutionary outcomes do not replicate, explained by the phenomenon of “hitchhiking” mutations, where neutral or deleterious genetic changes accompany beneficial ones, thereby diluting their selective advantage. This dynamic underscores how the intensity of selection shapes not only the viral genotype but also the composition and eventual dominance of variants within populations.

The study also tackled the complex interplay among three pivotal forces influencing viral fitness: infectivity, structural stability, and immune evasion. Their experiments, conducted absent any immune challenge, nonetheless resulted in the spontaneous emergence of most Omicron-associated mutations, emphasizing that enhanced infectivity was the prime driver of SARS-CoV-2 evolution. Yet, as community immunity rose globally, selective pressures began favoring mutations balancing receptor binding with immune escape capabilities, reflecting a nuanced adaptive compromise within the viral population.

Prof. Schreiber highlights that this innovative in vitro evolution platform is not confined to SARS-CoV-2. It can be applied broadly to other viruses of concern, enabling preemptive identification of potentially dangerous variants before they emerge clinically. This predictive power could prove indispensable in pandemic preparedness, guiding both surveillance strategies and the development of targeted interventions.

It is important to note that the persistence of Omicron in the human population involves conditions distinct from its initial emergence. Once established, even under weaker selection pressure, Omicron’s genetic composition remains stable, explaining its continued predominance. This observation underscores the critical need to protect and effectively treat immunocompromised individuals to limit chronic infections that fuel viral evolution.

The implications of these findings are profound. By replicating billions of human viral interactions within the confines of controlled laboratory settings over accelerated timescales, researchers have opened new horizons for anticipating viral trajectories. This capability could revolutionize how health authorities respond to emerging outbreaks, shifting from reactive containment to proactive intervention based on molecular evolutionary predictions.

Future pandemic responses may hinge on such innovative methodologies, which combine molecular biology, evolutionary theory, and cutting-edge biotechnology. This approach empowers scientists with unprecedented foresight into how viruses adapt, enabling more effective public health strategies and enhancing our collective resilience against viral threats yet to come.

As scientific communities worldwide digest these insights, the collaboration between the Weizmann Institute and Charles University serves as a testament to the power of international scientific cooperation. Together, they have not only demystified a critical chapter in COVID-19’s evolution but also laid a foundation for controlling future zoonotic crises through rigorous, predictive science.

Subject of Research: Viral evolution and pandemic prediction; SARS-CoV-2 evolution; in vitro evolution methods.

Article Title: Stringent selection drives convergence toward omicron-like SARS-CoV-2 receptor-binding motifs

Web References: Nature Communications Article

Keywords: SARS-CoV-2, coronavirus, Omicron variant, viral evolution, in vitro evolution, receptor binding, mutation, pandemic prediction, immunocompromised hosts, viral fitness, selection pressure, viral adaptation